Associated Papers
Detection of clinically relevant variants in the TP53 gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL.
Pavlova S et al.
Hemasphere, 2025
39840379 (PubMed )
Supplement: HEM3-9-e70065-s001.xlsx › Table_S5
Wild-type p53 upregulates an early onset breast cancer-associated gene GAS7 to suppress metastasis via GAS7-CYFIP1-mediated signaling pathway.
Chang JW et al.
Oncogene, 2018
29706651 (PubMed )
Supplement: 41388_2018_253_MOESM1_ESM.pdf
Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing.
Nahar R et al.
Nature Communications, 2018
29335443 (PubMed )
Supplement: 41467_2017_2584_MOESM3_ESM.xlsx › Pospileup
Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma.
Köbel M et al.
The Journal of Pathology. Clinical Research, 2016
27840695 (PubMed )
Supplement: CJP2-2-247-s008.xlsx › Sheet1
Select a paper to view details